Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Intravenous Iron Therapy With Ferric Carboxymaltose Compared With Oral Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

NCT03833336 is registered in ClinicalTrials.gov with Institut de Recerca Biomèdica de Lleida as lead sponsor.

NCT NCT03833336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Intravenous Iron Therapy With Ferric Carboxymaltose Compared With Oral Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)
Lead sponsor
Institut de Recerca Biomèdica de Lleida
Phase
Phase 3
Overall status
Completed
Start date
August 23, 2017
Completion date
December 20, 2024
Enrollment
72 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ferropenic anemia, heart failure with normal ejection fraction